Vanda Pharmaceuticals Inc. (VNDA) — 8-K Filings

8-K Filings (31)

• Vanda Pharmaceuticals Files 8-K — Dec 31, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on December 30, 2025, reporting other events and financial statements. The filing details the company's principal execut
• 8-K Filing — Dec 4, 2025
• 8-K Filing — Nov 28, 2025
• Vanda Pharmaceuticals Files 8-K on Financials — Oct 29, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Vanda Pharmaceuticals Files 8-K — Oct 1, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on October 1, 2025, to report other events and financial statements. The filing does not contain specific details about
• Vanda Pharmaceuticals Files 8-K on Shareholder Votes — Jun 5, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on June 5, 2025, to report on matters submitted to a vote of its security holders. The filing does not detail the specif
• Vanda Pharmaceuticals Files 8-K on Financials — May 7, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Vanda Pharmaceuticals Files 8-K for Regulation FD Disclosure — Mar 17, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on March 17, 2025, reporting an event on March 14, 2025. The filing pertains to a Regulation FD Disclosure and includes
• Vanda Pharmaceuticals Reports Director/Officer Changes — Feb 20, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on February 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of
• Vanda Pharmaceuticals Files 8-K on Financials — Feb 13, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on February 13, 2025, reporting on its results of operations and financial condition, as well as financial statements an
• Vanda Pharmaceuticals Files 8-K: Regulation FD Disclosure — Jan 27, 2025 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on January 27, 2025, reporting an event that occurred on January 25, 2025. The filing indicates a Regulation FD Disclosu
• Vanda Pharmaceuticals Files 8-K — Nov 6, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on November 6, 2024, to report on its results of operations and financial condition, as well as to file financial statem
• Vanda Pharmaceuticals Files 8-K — Oct 15, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on October 15, 2024, reporting other events and financial statements. The filing pertains to events that occurred on Oct
• Vanda Pharmaceuticals Files 8-K — Oct 3, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on October 3, 2024, reporting an amendment to its articles of incorporation or bylaws and financial statements/exhibits.
• Vanda Pharmaceuticals Files 8-K — Sep 19, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on September 19, 2024, to report other events and financial statements. The filing details the company's corporate struc
• Vanda Pharmaceuticals Files 8-K: Material Definitive Agreement — Aug 8, 2024 Risk: medium
  Vanda Pharmaceuticals Inc. announced on August 7, 2024, the entry into a material definitive agreement. The filing also indicates material modifications to the
• Vanda Pharmaceuticals Files 8-K on Financials — Jul 31, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on July 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Vanda Pharmaceuticals to be Acquired by Future Pak for $465M — Jun 20, 2024 Risk: medium
  Vanda Pharmaceuticals Inc. announced on June 19, 2024, that it has entered into a definitive agreement to be acquired by Future Pak, LLC. The transaction is val
• Vanda Pharmaceuticals Files 8-K Report — Jun 13, 2024 Risk: low
  On June 13, 2024, Vanda Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
• Vanda Pharmaceuticals Files 8-K — Jun 6, 2024 Risk: medium
  Vanda Pharmaceuticals Inc. filed an 8-K on June 6, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Vanda Pharmaceuticals Files 8-K — May 24, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on May 24, 2024, to report other events and financial statements. The filing does not contain specific details about the
• Vanda Pharmaceuticals Files 8-K on Shareholder Vote Matters — May 20, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on May 20, 2024, reporting on matters submitted to a vote of security holders as of May 17, 2024. The filing indicates t
• Vanda Pharmaceuticals Files 8-K on Financials — May 8, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements
• Vanda Pharmaceuticals Files 8-K — May 7, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on May 7, 2024, to report other events and financial statements. The filing does not detail specific transactions or fin
• Vanda Pharmaceuticals Files 8-K: Material Agreement Details — May 3, 2024 Risk: medium
  On May 3, 2024, Vanda Pharmaceuticals Inc. filed an 8-K report detailing a material definitive agreement. The filing also addresses modifications to the rights
• Vanda Pharmaceuticals Files 8-K: Material Agreement Details — Apr 17, 2024 Risk: medium
  On April 17, 2024, Vanda Pharmaceuticals Inc. announced a material definitive agreement related to its securities. The company also reported on other events and
• Vanda Pharmaceuticals Files 8-K — Apr 3, 2024 Risk: low
  Vanda Pharmaceuticals Inc. filed an 8-K on April 3, 2024, reporting on events that occurred on April 2, 2024. The filing primarily concerns other events and inc
• Vanda Pharmaceuticals to be Acquired for $465M — Mar 7, 2024 Risk: medium
  Vanda Pharmaceuticals Inc. announced on March 6, 2024, that it has entered into a definitive agreement to be acquired by FutureGen Acquisition Corp. for approxi
• Vanda Pharma Files 8-K on Officer/Director Changes & Compensation — Feb 21, 2024 Risk: medium
  Vanda Pharmaceuticals Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 16, 2024. The filing, under SEC File Number 001-34186
• Vanda Pharma Files 8-K on Operations & Financial Condition — Feb 7, 2024
  Vanda Pharmaceuticals Inc. filed an 8-K on February 7, 2024, to report on its results of operations and financial condition. This filing indicates that the comp
• Vanda Pharma Files 8-K for 'Other Events' on Feb 5, 2024 — Feb 5, 2024
  Vanda Pharmaceuticals Inc. filed an 8-K on February 5, 2024, to report an "Other Event" and "Financial Statements and Exhibits." This filing indicates that the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX